Shareholders meeting
Proceedings of 21st AGM held on August 10, 2026 via video conferencing
- All resolutions passed including appointment of new MD & CEO
- Chairman Dilip S. Shanghvi delivered speech on industry trends and SPARC's strategic focus
- Focus on oncology, immunology, and innovation-driven R&D
- Monetization of USFDA Paediatric Rare Disease Voucher for $195M strengthens finances
- Cost optimization and consolidation of labs improved efficiency
- Outgoing director Dr. Rajamannar thanked; new MD Anil Raghavan welcomed
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 SPARC — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add SPARC to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Sun Pharma Advanced Research Company Limited
Important.
The summary above is generated automatically from Sun Pharma Advanced Research Company Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.